

CITATION REPORT

List of articles citing

Bile Acids as Hormones: The FXR-FGF15/19 Pathway

DOI: 10.1159/000371670

Digestive Diseases, 2015, 33, 327-31.

Source: <https://exaly.com/paper-pdf/61233739/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
261	Liver CHIP-seq analysis in FGF19-treated mice reveals SHP as a global transcriptional partner of SREBP-2. 2015 , 16, 268		24
260	The FXR-FGF19 Gut-Liver Axis as a Novel "Hepatostat". 2015 , 149, 537-40		20
259	Postnatal Deletion of Fat Storage-inducing Transmembrane Protein 2 (FIT2/FITM2) Causes Lethal Enteropathy. 2015 , 290, 25686-99		32
258	Targeting the brain as a cure for type 2 diabetes. 2016 , 22, 709-11		7
257	Essential roles of bile acids and their nuclear receptors, FXR and PXR, in the cholestatic liver disease. 2016 , 20, 175-178		1
256	Crosstalk of HNF4 with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. 2016 , 6, 393-408		48
255	An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. 2016 , 151, 845-859		159
254	Role of farnesoid X receptor in cholestasis. 2016 , 17, 501-509		27
253	FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of <i>Kllotho</i> . 2016 , 30, 92-103		35
252	The interrelationship between bile acid and vitamin A homeostasis. 2017 , 1862, 496-512		34
251	Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice. 2017 , 152, 1126-1138. e69		
250	Short bowel syndrome results in increased gene expression associated with proliferation, inflammation, bile acid synthesis and immune system activation: RNA sequencing a zebrafish SBS model. 2017 , 18, 23		18
249	Bile acids and cardiovascular function in cirrhosis. 2017 , 37, 1420-1430		26
248	Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease. <i>Digestive Diseases</i> , 2017 , 35, 178-184	3.2	46
247	Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. 2017 , 66, 1182-1192. e60		
246	Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human <i>Defensin-1</i> and <i>-2</i> secretion by colonic epithelial cells. 2017 , 31, 3848-3857		15
245	Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. 2017 , 8, 15433		83

244	Bile acids and gestation. 2017 , 56, 90-100		31
243	Regulation of Energy Homeostasis After Gastric Bypass Surgery. 2017 , 19, 459-484		5
242	GATA4 Is Sufficient to Establish Jejunal Versus Ileal Identity in the Small Intestine. 2017 , 3, 422-446		24
241	Regulation of Liver Energy Balance by the Nuclear Receptors Farnesoid X Receptor and Peroxisome Proliferator Activated Receptor \square <i>Digestive Diseases</i> , 2017 , 35, 203-209	3.2	14
240	Complex interaction between circadian rhythm and diet on bile acid homeostasis in male rats. 2017 , 34, 1339-1353		35
239	Pregnane X receptor (PXR) deficiency improves high fat diet-induced obesity via induction of fibroblast growth factor 15 (FGF15) expression. 2017 , 142, 194-203		14
238	Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform. 2017 , 9, 1976-1990		89
237	Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. 2017 , 1, 1024-1042		82
236	Nutrient-sensing nuclear receptors PPAR α and FXR control liver energy balance. 2017 , 127, 1193-1201		86
235	Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases. <i>Frontiers in Pharmacology</i> , 2017 , 8, 162	5.6	22
234	Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System. 2017 , 11, 617		112
233	Bile Acid Receptor Farnesoid X Receptor: A Novel Therapeutic Target for Metabolic Diseases. 2017 , 6, 1		3
232	Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances. 2017 , 16, s58-s67		14
231	Fish oil feeding reverses hepatomegaly and disrupted hepatic function due to the lack of FXR signaling. 2017 , 42, 671-681		5
230	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. 2018 , 20, 1623-1631		11
229	FGF-19 agonism for NASH: a short study of a long disease. 2018 , 391, 1124-1126		6
228	NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 2018 , 391, 1174-1185		256
227	Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders. 2018 , 26, 792-800		94

226	Effects of supplemented isoenergetic diets varying in cereal fiber and protein content on the bile acid metabolic signature and relation to insulin resistance. 2018 , 8, 11		13
225	AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle. 2018 , 9, 540		25
224	Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. 2018 , 34, 90-96		17
223	Regulation of Hepatic Glucose Metabolism by FoxO Proteins, an Integrated Approach. 2018 , 127, 119-147		9
222	A gut-brain axis regulating glucose metabolism mediated by bile acids and competitive fibroblast growth factor actions at the hypothalamus. 2018 , 8, 37-50		34
221	Brown Adipose Tissue and Body Weight Regulation. 2018 , 117-132		2
220	No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model. 2018 , 42, 1238-1251		8
219	Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications. 2018 , 1864, 1326-1334		23
218	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018 , 67, 1890-1902	11.2	139
217	Bile acid receptors in the biliary tree: TGR5 in physiology and disease. 2018 , 1864, 1319-1325		63
216	Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. 2018 , 27, 22-41		298
215	Xenobiotic and endobiotic handling by the mucosal immune system. 2018 , 34, 404-412		2
214	Regulation of bile acid receptor activity. 2018 , 2, 180-185		22
213	Role of TGR5 (GPBAR1) in Liver Disease. 2018 , 38, 333-339		33
212	Bile Acids and Bile Flow: New Functions of Old Molecules. 2018 , 20-36.e6		
211	Making way for suppressing the FGF19/FGFR4 axis in cancer. 2018 , 10, 2457-2470		10
210	NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 2018 , 2, 1037-1050		63
209	Novel and emerging therapies for cholestatic liver diseases. 2018 , 38, 1520-1535		33

208	The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice. 2018 , 293, 10322-10330	
207	Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. 2018 , 9, 2590	33
206	An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. 2018 , 155, 1012-1016	31
205	Developmental regulation of the intestinal FGF19 system in domestic pigs. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, G647-G654	5.1 8
204	Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. 2018 , 98, 1983-2023	104
203	MAFB mediates the therapeutic effect of sleeve gastrectomy for obese diabetes mellitus by activation of FXR expression. 2018 , 51, e7312	1
202	New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs. 2019 , 104, 2463-2472	10
201	Hepatic cholesterol accumulation ascribed to the activation of ileum Fxr-Fgf15 pathway inhibiting hepatic Cyp7a1 in high-fat diet-induced obesity rats. 2019 , 232, 116638	23
200	Molecular tuning of farnesoid X receptor partial agonism. 2019 , 10, 2915	39
199	A Possible Mechanism of Metformin in Improving Insulin Resistance in Diabetic Rat Models. 2019 , 2019, 3248527	7
198	Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. 2019 , 10, 4971	171
197	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. 2019 , 16,	12
196	Mice depleted for Exchange Proteins Directly Activated by cAMP (Epac) exhibit irregular liver regeneration in response to partial hepatectomy. 2019 , 9, 13789	6
195	Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. 2019 , 60, 550-565	17
194	Duodenal-jejunal lining increases postprandial unconjugated bile acid responses and disrupts the bile acid-FXR-FGF19 axis in humans. 2019 , 93, 25-32	5
193	Targeting FXR in Cholestasis. 2019 , 256, 299-324	34
192	Metabolic Targets in Nonalcoholic Fatty Liver Disease. 2019 , 8, 247-267	48
191	Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis. 2019 , 294, 8732-8744	16

190	Nuclear receptors, cholesterol homeostasis and the immune system. 2019 , 191, 105364		11
189	Farnesoid X receptor: An important factor in blood glucose regulation. 2019 , 495, 29-34		8
188	FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis. <i>Diabetes</i> , 2019 , 68, 1315-1328	0.9	23
187	Emerging roles of bile acids in mucosal immunity and inflammation. 2019 , 12, 851-861		89
186	FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis. 2019 , 48, 460-474.e9		40
185	Gall bladder: The metabolic orchestrator. 2019 , 35, e3140		5
184	Inflammation and Cell Death During Cholestasis: The Evolving Role of Bile Acids. 2019 , 19, 215-228		17
183	Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. 2019 , 20, 189-197		1
182	Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. 2019 , 30, 235-243		24
181	Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1566	5.6	34
180	Evaluation of FGF-19 and Eklotoh as biomarkers in patients with intrahepatic cholestasis of pregnancy. 2019 , 15, 113-119		4
179	Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. 2019 , 20, 69-82		15
178	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. 2019 , 70, 483-493		77
177	Expression of Halo-hFGF18 and study of its effect on differentiation of ATDC5 cells. 2019 , 155, 8-14		1
176	Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. 2019 , 70, 735-744		42
175	Developing a Novel Ambulatory Total Parenteral Nutrition-Dependent Short Bowel Syndrome Animal Model. 2019 , 234, 13-19		1
174	Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. 2020 , 105,		5
173	MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice. <i>Hepatology</i> , 2020 , 71, 2118-2134	11.2	12

172	Diversification of host bile acids by members of the gut microbiota. <i>Gut Microbes</i> , 2020 , 11, 158-171	8.8	95
171	EKlotho gene variation is associated with liver damage in children with NAFLD. 2020 , 72, 411-419		27
170	Xyloglucan affects gut-liver circulating bile acid metabolism to improve liver damage in mice fed with high-fat diet. 2020 , 64, 103651		7
169	The Gut-Liver Axis in the Control of Energy Metabolism and Food Intake in Animals. 2020 , 8, 295-319		23
168	Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. 2020 , 19, 5-16		8
167	Developments in the study of gastrointestinal microbiome disorders affected by FGF19 in the occurrence and development of colorectal neoplasms. 2020 , 235, 4060-4069		2
166	Two apples a day lower serum cholesterol and improve cardiometabolic biomarkers in mildly hypercholesterolemic adults: a randomized, controlled, crossover trial. 2020 , 111, 307-318		27
165	Current and potential treatments for primary biliary cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 306-315	18.8	23
164	PL-S2, a homogeneous polysaccharide from <i>Radix Puerariae lobatae</i> , attenuates hyperlipidemia via farnesoid X receptor (FXR) pathway-modulated bile acid metabolism. 2020 , 165, 1694-1705		5
163	Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes. 2020 , 2020, 6138438		7
162	Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascular Disease. 2020 , 22, 47		11
161	Cholecystectomy as a risk factor for non-alcoholic fatty liver disease development. 2020 , 22, 1513-1520		3
160	Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A. 2020 , 11, 5969		17
159	Black bean protein concentrate ameliorates hepatic steatosis by decreasing lipogenesis and increasing fatty acid oxidation in rats fed a high fat-sucrose diet. 2020 , 11, 10341-10350		4
158	Intestinal Inflammation Alters the Expression of Hepatic Bile Acid Receptors Causing Liver Impairment. 2020 , 71, 189-196		5
157	Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. 2020 , 25, 251-260		6
156	What's eating you? An update on <i>Giardia</i> , the microbiome and the immune response. 2020 , 58, 87-92		3
155	Organoids to Study Intestinal Nutrient Transport, Drug Uptake and Metabolism - Update to the Human Model and Expansion of Applications. 2020 , 8, 577656		16

154	Mammalian Sterols. 2020 ,		0
153	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	20
152	FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. 2020 , 11, 601349		9
151	A -Driven Transgene Modulates Enterohepatic Bile Acid Homeostasis and Response to an -6-Enriched High-Fat Diet. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	2
150	Development and validation of an ambulatory piglet model for short bowel syndrome with ileo-colonic anastomosis. 2020 , 245, 1049-1057		2
149	Molecular regulators of lipid metabolism in the intestine - Underestimated therapeutic targets for obesity?. 2020 , 178, 114091		2
148	Bile Acid Supplementation Improves Murine Pancreatitis in Association With the Gut Microbiota. 2020 , 11, 650		5
147	Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes. 2020 , 12, 44		3
146	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. 2020 , 11, e00131		26
145	Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver. 2020 , 390, 111949		7
144	Targeting bile acid metabolism in obesity reduction: A systematic review and meta-analysis. 2020 , 21, e13017		12
143	Obeticholic acid for the treatment of nonalcoholic steatohepatitis. 2020 , 14, 311-321		13
142	Unequal Effects of Myosin 5B Mutations in Liver and Intestine Determine the Clinical Presentation of Low-Gamma-Glutamyltransferase Cholestasis. <i>Hepatology</i> , 2020 , 72, 1461-1468	11.2	8
141	Lactobacillus plantarum LP33 attenuates Pb-induced hepatic injury in rats by reducing oxidative stress and inflammation and promoting Pb excretion. 2020 , 143, 111533		7
140	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. 2020 , 55, 102759		24
139	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. 2020 , 21, 953-967		17
138	Intestinal barrier function and metabolic/liver diseases. 2020 , 4, 81-87		10
137	New Therapeutic Targets in Autoimmune Cholangiopathies. 2020 , 7, 117		12

136	Dietary Fiber from Oat and Rye Brans Ameliorate Western Diet-Induced Body Weight Gain and Hepatic Inflammation by the Modulation of Short-Chain Fatty Acids, Bile Acids, and Tryptophan Metabolism. 2021 , 65, e1900580		14
135	The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. <i>Hepatology</i> , 2021 , 73, 126-143	11.2	22
134	Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. 2021 , 160, 219-231.e1		74
133	Dietary fat, bile acid metabolism and colorectal cancer. 2021 , 73, 347-355		20
132	Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation. <i>Drug Metabolism and Disposition</i> , 2021 , 49, 12-19	4	1
131	Enterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism. 2021 , 165, 108757		4
130	Investigational drugs in early phase development for primary biliary cholangitis. 2021 , 30, 131-141		2
129	Hepatic Autophagy Deficiency Remodels Gut Microbiota for Adaptive Protection via FGF15-FGFR4 Signaling. 2021 , 11, 973-997		7
128	Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice. 2021 , 14, 500-510		11
127	Hepatic metabolic regulation by nuclear factor E4BP4. 2021 , 66, R15-R21		0
126	Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism. 2021 , 3, 59-74		10
125	ZDY01 inhibits choline-induced atherosclerosis through CDCA-FXR-FGF15 axis. 2021 , 12, 9932-9946		3
124	Gastrointestinal Physiology and Aging. 2021 , 1-46		
123	Bile Acids in Control of the Gut-Liver-Axis. 2021 , 59, 63-68		1
122	Gastrointestinal Physiology and Aging. 2021 , 155-200		
121	TL Downregulates the Ileal Expression of Genes Involved in Immune Responses in Broiler Chickens to Improve Growth Performance. 2021 , 9,		2
120	Exposure to high fructose corn syrup during adolescence in the mouse alters hepatic metabolism and the microbiome in a sex-specific manner. 2021 , 599, 1487-1511		5
119	Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum. 2021 , 12, 420-425		2

118	Western Diet Aggravated Carbon Tetrachloride-Induced Chronic Liver Injury by Disturbing Gut Microbiota and Bile Acid Metabolism. 2021 , 65, e2000811		4
117	Linderae Radix Ethanol Extract Alleviates Diet-Induced Hyperlipidemia by Regulating Bile Acid Metabolism Through gut Microbiota. <i>Frontiers in Pharmacology</i> , 2021 , 12, 627920	5.6	4
116	An insight into the mechanism and molecular basis of dysfunctional immune response involved in cholestasis. 2021 , 92, 107328		3
115	Deletion of Intestinal SHP Impairs Short-term Response to Cholic Acid Challenge in Male Mice. 2021 , 162,		3
114	Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer. 2021 , 186, 114430		4
113	The hypothalamus for whole-body physiology: from metabolism to aging. 2021 , 1		8
112	The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	6
111	Gaussian graphical modeling of the serum exposome and metabolome reveals interactions between environmental chemicals and endogenous metabolites. 2021 , 11, 7607		0
110	Bile acids as novel enhancers of CNS targeting antitumor drugs: a comprehensive review. 2021 , 26, 617-633		2
109	Gender and gut microbiota composition determine hepatic bile acid, metabolic and inflammatory response to a single fast-food meal in healthy adults. 2021 , 40, 2609-2619		2
108	The therapeutic landscape of hepatocellular carcinoma.. 2021 , 2, 505-552		3
107	Absence of muricholic acid due to Cyp2c-deficiency protects against high fat diet-induced obesity in male mice but promotes liver damage.		
106	The role of bile acid subtypes in the diagnosis of cholangiocarcinoma. 2021 ,		0
105	Identifying a Novel Bile Salt Hydrolase from the Keystone Gut Bacterium. 2021 , 9,		3
104	Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. 2021 , 3, 100255		11
103	Endoplasmic reticulum stress in intestinal inflammation: implications of bile acids. 2021 , 87, 275-282		
102	Anti-fibrotic treatments for chronic liver diseases: The present and the future. 2021 , 27, 413-424		2
101	The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma. 2021 , 191, 1180-1192		3

100	Dysbiosis of gut microbiota after cholecystectomy is associated with non-alcoholic fatty liver disease in mice. 2021 , 11, 2329		0
99	Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury. 2021 , 10,		5
98	Dynamics of the enterohepatic circulation of bile acids in healthy humans. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 321, G55-G66	5.1	2
97	Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer.. 2021 , 2, 21		7
96	Genetic Disorders of Bile Acid Transport. 2021 , 18, 237-242		0
95	Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. 2021 , 12, 718783		8
94	Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review. 2021 , 1-11		1
93	Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. 2021 , 41, 2534-2546		2
92	Drug Screening, Oral Bioavailability and Regulatory Aspects: A Need for Human Organoids. 2021 , 13,		2
91	The pathogenesis, models and therapeutic advances of primary biliary cholangitis. 2021 , 140, 111754		2
90	Quantification of serum fibroblast growth factor-19 concentration in healthy dogs before and after feeding. 2021 , 82, 676-682		
89	Colon cancer checks in when bile acids check out: the bile acid-nuclear receptor axis in colon cancer. 2021 , 65, 1015-1024		1
88	Next Generation Microbiome Research: Identification of Keystone Species in the Metabolic Regulation of Host-Gut Microbiota Interplay. 2021 , 9, 719072		2
87	Liver X receptor regulates bile volume and the expression of aquaporins and cystic fibrosis transmembrane conductance regulator in the gallbladder. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 321, G243-G251	5.1	1
86	Synthesis of 12Methyl-18--bile Acids. 2021 , 6, 25019-25039		0
85	Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets. 2021 , 5, 142-150		3
84	Cholesterol-lowering effects of taurine through the reduction of ileal FXR signaling due to the alteration of ileal bile acid composition. 2021 , 53, 1523-1532		2
83	Cyp2c-deficiency depletes muricholic acids and protects against high-fat diet-induced obesity in male mice but promotes liver damage. 2021 , 53, 101326		2

82	Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury. 2021 , 157, 106843		13
81	Depletion of gut microbiota induces skeletal muscle atrophy by FXR-FGF15/19 signalling. 2021 , 53, 508-522		11
80	Bile Acids and TGR5 (Gpbar1) Signaling. 2020 , 81-100		2
79	Oxysterols and Bile Acid Act as Signaling Molecules That Regulate Cholesterol Homeostasis: Nuclear Receptors LXR, FXR, and Fibroblast Growth Factor 15/19. 2020 , 117-143		1
78	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. 2020 , 134, 1775-1799		9
77	Bromodomain inhibition reveals FGF15/19 as a target of epigenetic regulation and metabolic control.		2
76	Deletion of intestinal SHP impairs short-term response to cholic acid challenge in mice.		1
75	BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination. 2020 , 6,		5
74	RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism. 2017 , 127, 3741-3754		38
73	Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. <i>Journal of Clinical and Translational Hepatology</i> , 2020 , 8, 49-60	5.2	13
72	The Therapeutic Role of Xenobiotic Nuclear Receptors Against Metabolic Syndrome. 2019 , 20, 15-22		10
71	Gut-liver axis signaling in portal hypertension. 2019 , 25, 5897-5917		35
70	Luminally Active Therapies: Pancreatic Enzymes, Bile Acids, Bile Acid Binders, Antimicrobials, Probiotics, and Prebiotics in Short Bowel Syndrome. 2016 , 227-239		
69	Recent advances in understanding cross-talk between Bile Acids and Gut Microbiota. 024-034		
68	Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. 2019 , 29, 17-23		2
67	Gut dysbiosis protects against liver injury in autophagy deficient mice by FXR-FGF15 feedback signaling.		
66	Effect of changes of gut microbiota in constipation on lipid metabolism. 2020 , 28, 341-346		
65	Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease.. 2020 , 18, 61-69		0

64	Host response to cholestyramine can be mediated by the gut microbiota.		0
63	Defective FXR-SHP Regulation in Obesity Aberrantly Increases Expression, Promoting Insulin Resistance and Fatty Liver. <i>Diabetes</i> , 2021 , 70, 733-744	0.9	5
62	Chapter 5:The Interaction of Nutrition with Nuclear Receptors in Obesity and Diabetes. 2020 , 94-163		
61	Bile acid supplementation improves murine pancreatitis in association with the gut microbiota.		
60	. <i>Drug Metabolism and Disposition</i> , 2021 ,	4	5
59	A short report on NGM282/aldifermin for the treatment of nonalcoholic steatohepatitis (NASH). <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 1-7	6.4	2
58	Endocrine pheromones couple fat rationing to dauer diapause through HNF4 β nuclear receptors. <i>Science China Life Sciences</i> , 2021 , 64, 2153	8.5	2
57	Fecal Microbiome and Bile Acid Metabolome in Adult Short Bowel Syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2021 ,	5.1	0
56	Ceramide signaling in the gut.. <i>Molecular and Cellular Endocrinology</i> , 2022 , 544, 111554	4.4	1
55	Pleiotropic roles of FXR in liver and colorectal cancers.. <i>Molecular and Cellular Endocrinology</i> , 2022 , 111543	4.1	0
54	Bile Acids as a New Type of Steroid Hormones Regulating Nonspecific Energy Expenditure of the Body (Review). <i>Sovremennye Tehnologii V Medicine</i> , 2021 , 12, 114-127	1.2	2
53	A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver.. <i>Metabolites</i> , 2022 , 12,	5.6	1
52	Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022 , 000, 000-000	5.2	0
51	An Update on Novel Pharmacological Agents for Primary Sclerosing Cholangitis.. <i>Expert Opinion on Therapeutic Targets</i> , 2022 ,	6.4	2
50	Identification and Distribution of Sterols, Bile Acids, and Acylcarnitines by LC-MS/MS in Humans, Mice, and Pigs-A Qualitative Analysis.. <i>Metabolites</i> , 2022 , 12,	5.6	2
49	Bromodomain Inhibition Reveals FGF15/19 as a Target of Epigenetic Regulation and Metabolic Control.. <i>Diabetes</i> , 2022 ,	0.9	0
48	Kaempferol acts on bile acid signaling and gut microbiota to attenuate the tumor burden in ApcMin/+ mice.. <i>European Journal of Pharmacology</i> , 2022 , 918, 174773	5.3	3
47	Mechanisms & Molecules: What are the treatment targets for PBC?. <i>Hepatology</i> , 2022 ,	11.2	0

46	Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	5
45	The effectiveness of small heterodimer partner and FGF 19 levels in prediction of perinatal morbidity in intrahepatic cholestasis of pregnancy.. <i>Journal of Obstetrics and Gynaecology</i> , 2022 , 1-5	1.3	
44	A Recent Ten-Year Perspective: Bile Acid Metabolism and Signaling.. <i>Molecules</i> , 2022 , 27,	4.8	2
43	Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	3
42	Role of microRNA-185 in the FoxO1-CYP7A1 mediated regulation of bile acid and cholesterol metabolism: A novel target for drug discovery?. <i>Atherosclerosis</i> , 2022 ,	3.1	0
41	Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.. <i>Journal of Clinical Medicine</i> , 2021 , 11,	5.1	2
40	Newer variants of progressive familial intrahepatic cholestasis.. <i>World Journal of Hepatology</i> , 2021 , 13, 2024-2038	3.4	0
39	Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease.. <i>Comprehensive Physiology</i> , 2021 , 12, 2719-2730	7.7	0
38	Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 796590	5.6	0
37	The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE-/-FXR-/- Mice.. <i>Endocrinology and Metabolism</i> , 2021 , 36, 1243-1253	3.5	1
36	Antibiotic Therapy as a Risk Factor of Obesity Development in Children. 2020 , 268-290		
35	Data_Sheet_1.pdf. 2020 ,		
34	Image_1.TIF. 2020 ,		
33	Image_2.TIF. 2020 ,		
32	Image_3.TIF. 2020 ,		
31	Table_1.doc. 2020 ,		
30	Reactive Oxygen Species Induce Fatty Liver and Ischemia-Reperfusion Injury by Promoting Inflammation and Cell Death.. <i>Frontiers in Immunology</i> , 2022 , 13, 870239	8.4	6
29	Effects of Acute and Chronic Resistance Exercise on the Skeletal Muscle Metabolome. <i>Metabolites</i> , 2022 , 12, 445	5.6	2

28	Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics. <i>Biomedicines</i> , 2022 , 10, 1288	4.8	2
27	Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 6046	6.3	2
26	Dietary fiber-based regulation of bile salt hydrolase activity in the gut microbiota and its relevance to human disease. <i>Gut Microbes</i> , 2022 , 14,	8.8	0
25	The early faecal microbiota transfer alters bile acid circulation and amino acid transport of the small intestine in piglets. <i>Journal of Animal Physiology and Animal Nutrition</i> ,	2.6	0
24	Feeding activates FGF15-SHP-TFEB-mediated lipophagy in the gut. <i>EMBO Journal</i> ,	13	0
23	Bile acid metabolism and signaling, the microbiota, and metabolic disease. 2022 , 108238		1
22	Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study. <i>Hepatology International</i> ,	8.8	
21	Gut associated metabolites and their roles in <i>Clostridioides difficile</i> pathogenesis. <i>Gut Microbes</i> , 2022 , 14,	8.8	0
20	New Insights into Bile Acids Related Signaling Pathways in the Onset of Colorectal Cancer. 2022 , 14, 2964		1
19	Approaches to discern if microbiome associations reflect causation in metabolic and immune disorders. 2022 , 14,		0
18	Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-Arm Pilot Study in Patients with T2DM. 2022 ,		0
17	Preventive Effects of L-Glutamine on High-Fat Diet-Induced Metabolic Disorders Linking with Regulation of Intestinal Barrier Integrity, Hepatic Lipid Metabolism, and Gut Microbiota in Rats. 2022 , 70, 11923-11934		0
16	L-Theanine regulates lipid metabolism by modulating gut microbiota and bile acid metabolism.		0
15	Pentacyclic triterpenes modulate farnesoid X receptor expression in colonic epithelial cells: implications for colonic secretory function.. 2022 , 102569		0
14	Effects of oral tauroursodeoxycholic acid and/or intestinal probiotics on serum biochemical indexes and bile composition in patients with cholecystolithiasis. 13,		0
13	A history of research into the physiology of bile, from Hippocrates to molecular medicine. 2022 , 20, 33-44		0
12	Bile acids as inflammatory mediators and modulators of intestinal permeability. 13,		0
11	Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation. 2022 , 11, 3983		0

- 10 Toward a Cell Culture Model of Portal Axis Lipid Handling. ○
- 9 Management of metabolic-associated fatty liver disease: The diabetology perspective. 29, 126-143 ○
- 8 Ingestion of whey protein and Lecithin exerts opposite effects on intestinal FGF15 and serotonin secretion in mice. 14, ○
- 7 Ganoderma lucidum polysaccharides improve lipid metabolism against high-fat diet-induced dyslipidemia. 2023, 309, 116321 ○
- 6 Bile acids as modulators of gut microbiota composition and function. 2023, 15, 1 ○
- 5 The gut signals to AGRP-expressing cells of the pituitary to control glucose homeostasis. 2023, 133, ○
- 4 First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. 2023, 18, 181-193 ○
- 3 Smooth muscle cells, interstitial cells and neurons in the gallbladder (GB): Functional syncytium of electrical rhythmicity and GB motility (Review). 2023, 51, ○
- 2 Exploring the Structural and Functional Diversity among FGF Signals: A Comparative Study of Human, Mouse, and Xenopus FGF Ligands in Embryonic Development and Cancer Pathogenesis. 2023, 24, 7556 ○
- 1 Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease. ○